Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Zabrina Watkins Our passion Our people “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Traditional Feb. 28, 2025 – denosumab-bmwo (Osenvelt) BLA approval; denosumab-bmwo (Osenvelt) is a biosimilar to reference drug denosumab (Xgeva) RANK ligand inhibitor Osenvelt is indicated for (1)...

Tennessee pharmacies In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were...

Home Other Navigation Pharmacy + Providers Commercial Formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series Prescription Drug Guide NetResults™...

Managed Markets Insight & Technology (MMIT)

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...